HealthDay News — Recommendations for the diagnosis and management of severe acquired aplastic anemia are presented in a clinical practice guideline issued by the American Society of Hematology and ...
A Prescription Drug User Fee Act target date of December 10, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
Add Yahoo as a preferred source to see more of our stories on Google. Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell ...
What Is Omisirge, and Why Does It Matter? Omisirge (omidubicel-onlv) is a type of cell therapy made from umbilical cord blood. It helps your body make new blood cells after a stem cell transplant.
DUBLIN, IRELAND AND LONDON, UK = / ACCESS Newswire / December 8, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation today ...
The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...
On the surface, Owen Ho looked fine. But on the inside, it was a different story. Ho, 42, was exhausted. He couldn’t muster up the strength to exercise even though months earlier, six-hour bike rides ...
GRAND RAPIDS, Mich. — At just 18 years old, Lilly VandenBosch has already faced a lifetime of challenges. Diagnosed with aplastic anemia, a rare blood disorder, at the age of 7, her journey has been ...
Aplastic anemia is characterized by severe deficiencies in peripheral-blood platelets, white cells, and red cells. These defects in mature cells occur because aplastic bone marrow contains severely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results